Patents by Inventor Ira H. Pastan
Ira H. Pastan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190085078Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: ApplicationFiled: August 21, 2018Publication date: March 21, 2019Applicant: The United States of America,as represented by the Secretary,Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Publication number: 20180362659Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are promising therapeutic agents.Type: ApplicationFiled: August 20, 2018Publication date: December 20, 2018Inventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
-
Publication number: 20180318435Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.Type: ApplicationFiled: November 10, 2016Publication date: November 8, 2018Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Service, Sanford ResearchInventors: Ira H. Pastan, Tapan Bera, Satoshi Nagata, Tomoko Ise, Yasuhiro Abe
-
Publication number: 20180311346Abstract: Regional, tumor-targeted, cytotoxic therapy, such as D2C7-immunotoxin (D2C7-IT), not only specifically target and destroy tumor cells, but in the process initiate immune events that promote an in situ vaccine effect. The antitumor effects are amplified by immune checkpoint blockade which engenders a long-term systemic immune response that effectively eliminates all tumor cells.Type: ApplicationFiled: November 4, 2016Publication date: November 1, 2018Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN, SERVICES, NATIONAL INSTITUTES OF HEALTHInventors: Darell Bigner, Vidyalakshmi Chandramohan, Smita Nair, Matthias Gromeier, Xuhui Bao, Ira H. Pastan
-
Patent number: 10111927Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: GrantFiled: April 17, 2017Date of Patent: October 30, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Masanori Onda, Wenhai Liu
-
Patent number: 10072084Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: GrantFiled: October 11, 2016Date of Patent: September 11, 2018Assignees: Duke University, The United States of America as Represented by the Secretary Department of Health and Human Services (NIH)Inventors: Darell D. Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles Pegram
-
Patent number: 10072078Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: September 18, 2013Date of Patent: September 11, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
-
Patent number: 10052382Abstract: High affinity antibodies were made to gangliosides expressed on tumor cells. The antibodies can be used analytically, diagnostically, therapeutically, and theranostically. The antibodies may be used to target cytotoxic reagents to tumor cells, thus minimizing full-body toxicity. The antibodies may also be used with out added cytotoxin. The antibodies may be detectably labeled or labelable for analytic and diagnostic purposes. The combination of specificity and affinity of the antibodies render them particularly useful.Type: GrantFiled: June 2, 2016Date of Patent: August 21, 2018Assignees: Duke University, The United States of America as Represented by the Secretary of Health (NIH)Inventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Hailan Piao
-
Patent number: 10053514Abstract: We have constructed a polynucleotide encoding a bispecific antibody engaging molecule which has one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The polynucleotide is codon optimized for expression in CHO cells. The subunits of the engaging molecules are organized to achieve greater efficiency. These are therapeutic agents.Type: GrantFiled: July 9, 2014Date of Patent: August 21, 2018Assignees: Duke University, The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of HealthInventors: Darell D. Bigner, John Sampson, Chien-Tsun Kuan, Mingqing Cai, Bryan D. Choi, Patrick C. Gedeon, Ira H. Pastan
-
Patent number: 9868774Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a) an antigen binding domain of HA22, a transmembrane domain, and an intracellular T cell signaling domain; or b) an antigen binding domain of BL22, a transmembrane domain, and an intracellular T cell signaling domain comprising CD28 and/or CD137. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.Type: GrantFiled: October 19, 2012Date of Patent: January 16, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Rimas J. Orentas, Crystal L. Mackall, Ira H. Pastan
-
Publication number: 20170369535Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: September 1, 2017Publication date: December 28, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and HumanInventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Aaron Vassall, Richard Beers, Jaime Eberle, Wenhai Liu
-
Patent number: 9803022Abstract: Described herein is the use of rabbit hybridoma technology, along with a panel of truncated mesothelin domain fragments, to identify anti-mesothelin mAbs that bind specific regions of mesothelin. In one aspect of the present disclosure, the rabbit mAbs bind an epitope that is not part of Region I. In particular, the identified mAbs (YP187, YP223, YP218 and YP3) bind either Region II (391-486), Region III (487-581) or a native conformation of mesothelin with subnanomolar affinity. These antibodies do not compete for binding with the mesothelin-specific immunotoxin SS1P or mesothelin-specific antibody MORAb-009. In another aspect, disclosed is a high-affinity rabbit mAb that binds Region I of mesothelin (YP158). YP158 binds native mesothelin protein in cancer cells and tissues with high affinity and specificity.Type: GrantFiled: April 28, 2016Date of Patent: October 31, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Mitchell Ho, Ira H. Pastan, Yen T. Phung, Yifan Zhang, Wei Gao, Raffit Hassan
-
Patent number: 9765123Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: GrantFiled: April 11, 2016Date of Patent: September 19, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Aaron Vassall, Richard Beers, Jaime Eberle, Wenhai Liu
-
Publication number: 20170216398Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and phaxinaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: April 17, 2017Publication date: August 3, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Ira H. Pastan, Masanori Onda, Wenhai Liu
-
Patent number: 9676858Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific. These may be used as therapeutic agents.Type: GrantFiled: June 7, 2013Date of Patent: June 13, 2017Assignees: Duke University, The United States of America as represented by the secretary, Department of Health and Human Services (NIH)Inventors: Darell Bigner, Chien-Tsun Kuan, John Sampson, Bryan Choi, Ira H. Pastan, Patrick C. Gedeon
-
Publication number: 20170145097Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: ApplicationFiled: February 3, 2017Publication date: May 25, 2017Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human ServicesInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Patent number: 9657066Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more of amino acid residues E420, D463, Y481, L516, R563, D581, D589, and K606, wherein the amino acid residues are defined by reference to SEQ ID NO: 1. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: GrantFiled: October 30, 2015Date of Patent: May 23, 2017Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Ira H. Pastan, Masanori Onda, Wenhai Liu
-
Patent number: 9598492Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.Type: GrantFiled: February 1, 2016Date of Patent: March 21, 2017Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
-
Publication number: 20170051072Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: June 23, 2016Publication date: February 23, 2017Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
-
Publication number: 20170051064Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: October 11, 2016Publication date: February 23, 2017Applicants: Duke University, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES , NInventors: Darell D. Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles Pegram